The Abu Dhabi Department of Health announced the removal of the dangerous warning against the use of statin drugs during pregnancy, and attributed this decision to the recommendations of the US Food and Drug Administration to remove the warning related to contraindications to statin use in all pregnant patients, as the US Food and Drug Administration “FDA” considers contraindications to use. As a serious warning, it is only added when the risk of using the drug clearly outweighs any potential benefit, and the benefits of statins may include the prevention of serious or fatal infections in some pregnant patients who are at very high risk, so it cannot be generalized that statins are prohibited for all pregnant women.
In a circular issued by the Department of Health, the Department of Health indicated that patients who take statin drugs should inform the health care professional when they are pregnant or suspect pregnancy, so that the health care professional can provide the necessary recommendations regarding the use of statins during pregnancy and lactation, pointing out that patients at risk should Having a heart attack or stroke who need statins after giving birth Not breast-feeding and using alternatives such as infant formula.
The department called on health professionals to stop using statin treatment in most pregnant patients, or they can consider the ongoing treatment needs of the patient, especially those at very high risk of cardiovascular events during pregnancy, with the need to discuss with the patient regarding stopping taking statin drugs during breastfeeding, With the need to reassure patients that it is safe to prescribe statin drugs to a patient who can become pregnant, as well as reassure pregnant women who took these drugs before or at the beginning of pregnancy that they are not likely to affect the fetus.
The department pointed out that the mentioned medicines are safe to use and have not been withdrawn from the market, and called for reporting any side effects resulting from the use of medical products to the pharmacovigilance program through the electronic reporting system.
The Abu Dhabi Department of Health announced the removal of the dangerous warning against the use of statin drugs during pregnancy, and attributed this decision to the recommendations of the US Food and Drug Administration to remove the warning related to contraindications to statin use in all pregnant patients, as the US Food and Drug Administration “FDA” considers contraindications to use. As a serious warning, it is only added when the risk of using the drug clearly outweighs any potential benefit, and the benefits of statins may include the prevention of serious or fatal infections in some pregnant patients who are at very high risk, so it cannot be generalized that statins are prohibited for all pregnant women.
In a circular issued by the Department of Health, the Department of Health indicated that patients who take statin drugs should inform the health care professional when they are pregnant or suspect pregnancy, so that the health care professional can provide the necessary recommendations regarding the use of statins during pregnancy and lactation, pointing out that patients at risk should Having a heart attack or stroke who need statins after giving birth Not breast-feeding and using alternatives such as infant formula.
The department called on health professionals to stop using statin treatment in most pregnant patients, or they can consider the ongoing treatment needs of the patient, especially those at very high risk of cardiovascular events during pregnancy, with the need to discuss with the patient regarding stopping taking statin drugs during breastfeeding, With the need to reassure patients that it is safe to prescribe statin drugs to a patient who can become pregnant, as well as reassure pregnant women who took these drugs before or at the beginning of pregnancy that they are not likely to affect the fetus.
The department pointed out that the mentioned medicines are safe to use and have not been withdrawn from the market, and called for reporting any side effects resulting from the use of medical products to the pharmacovigilance program through the electronic reporting system.
The Abu Dhabi Department of Health announced the removal of the dangerous warning against the use of statin drugs during pregnancy, and attributed this decision to the recommendations of the US Food and Drug Administration to remove the warning related to contraindications to statin use in all pregnant patients, as the US Food and Drug Administration “FDA” considers contraindications to use. As a serious warning, it is only added when the risk of using the drug clearly outweighs any potential benefit, and the benefits of statins may include the prevention of serious or fatal infections in some pregnant patients who are at very high risk, so it cannot be generalized that statins are prohibited for all pregnant women.
In a circular issued by the Department of Health, the Department of Health indicated that patients who take statin drugs should inform the health care professional when they are pregnant or suspect pregnancy, so that the health care professional can provide the necessary recommendations regarding the use of statins during pregnancy and lactation, pointing out that patients at risk should Having a heart attack or stroke who need statins after giving birth Not breast-feeding and using alternatives such as infant formula.
The department called on health professionals to stop using statin treatment in most pregnant patients, or they can consider the ongoing treatment needs of the patient, especially those at very high risk of cardiovascular events during pregnancy, with the need to discuss with the patient regarding stopping taking statin drugs during breastfeeding, With the need to reassure patients that it is safe to prescribe statin drugs to a patient who can become pregnant, as well as reassure pregnant women who took these drugs before or at the beginning of pregnancy that they are not likely to affect the fetus.
The department pointed out that the mentioned medicines are safe to use and have not been withdrawn from the market, and called for reporting any side effects resulting from the use of medical products to the pharmacovigilance program through the electronic reporting system.
The Abu Dhabi Department of Health announced the removal of the dangerous warning against the use of statin drugs during pregnancy, and attributed this decision to the recommendations of the US Food and Drug Administration to remove the warning related to contraindications to statin use in all pregnant patients, as the US Food and Drug Administration “FDA” considers contraindications to use. As a serious warning, it is only added when the risk of using the drug clearly outweighs any potential benefit, and the benefits of statins may include the prevention of serious or fatal infections in some pregnant patients who are at very high risk, so it cannot be generalized that statins are prohibited for all pregnant women.
In a circular issued by the Department of Health, the Department of Health indicated that patients who take statin drugs should inform the health care professional when they are pregnant or suspect pregnancy, so that the health care professional can provide the necessary recommendations regarding the use of statins during pregnancy and lactation, pointing out that patients at risk should Having a heart attack or stroke who need statins after giving birth Not breast-feeding and using alternatives such as infant formula.
The department called on health professionals to stop using statin treatment in most pregnant patients, or they can consider the ongoing treatment needs of the patient, especially those at very high risk of cardiovascular events during pregnancy, with the need to discuss with the patient regarding stopping taking statin drugs during breastfeeding, With the need to reassure patients that it is safe to prescribe statin drugs to a patient who can become pregnant, as well as reassure pregnant women who took these drugs before or at the beginning of pregnancy that they are not likely to affect the fetus.
The department pointed out that the mentioned medicines are safe to use and have not been withdrawn from the market, and called for reporting any side effects resulting from the use of medical products to the pharmacovigilance program through the electronic reporting system.